Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer

Published:2012-10-29 Issue:10 Volume:7 Page:e44368
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kuzumaki Naoko,Suzuki Atsuo,Narita Michiko,Hosoya Takahiro,Nagasawa Atsumi,Imai Satoshi,Yamamizu Kohei,Morita Hiroshi,Suzuki Tsutomu,Okada Yohei,Okano Hirotaka James,Yamashita Jun K.,Okano Hideyuki,Narita Minoru

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference21 articles.

1. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;JH Schiller;N Engl J Med,2002

2. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy;AE Wakeling;Cancer Res,2002

3. ErbB-targeted therapeutic approaches in human cancer;CL Arteaga;Exp Cell Res,2003

4. Epidermal growth factor receptor: mechanisms of activation and signalling;RN Jorissen;Exp Cell Res,2003

5. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib;S Kobayashi;N Engl J Med,2005

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

2. Expression heterogeneity, tumor immune characteristics and the prognosis effects of OPRL1 in patients with tumors: a pan-cancer study combined with bioinformation analyses and in vitro validation;Anesthesiology and Perioperative Science;2024-01-23

3. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?;Translational Oncology;2021-05

4. Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation;Frontiers in Pharmacology;2021-04-22

5. Unraveling the Molecular Nexus between GPCRs, ERS, and EMT;Mediators of Inflammation;2021-03-02